What does this video actually claim?
The TikTok from @shopinseason focuses on "Ozempic face," using hashtags that suggest celebrities like Kylie Jenner, Kelly Osbourne, and Scott Disick have experienced facial changes from GLP-1 medications. The video implies these public figures developed the gaunt, aged appearance that's become associated with rapid weight loss from semaglutide and similar drugs.
However, the video doesn't explicitly state these celebrities used GLP-1 medications. It's mostly speculation based on visible weight changes and timing.
Is "Ozempic face" actually real?
Yes, facial volume loss from rapid weight loss is well-documented, though it's not specific to GLP-1 medications. Any significant weight reduction can cause loss of facial fat pads, leading to a hollow, aged appearance around the cheeks, temples, and under-eyes.
The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% average weight loss with 2.4mg semaglutide over 68 weeks. When someone loses 30-50 pounds quickly, facial fat disappears along with body fat.
Dermatologists report increased demand for facial fillers among patients using GLP-1 medications, but this reflects the speed of weight loss rather than a drug-specific side effect.
What about the celebrity claims?
Most of these celebrity attributions are pure speculation. Kelly Osbourne has openly discussed using Ozempic, making her inclusion more reasonable. But there's no verified evidence that Kylie Jenner, Jennifer Lopez, or most others listed have used GLP-1 medications.
The creator is essentially playing a guessing game based on before-and-after photos. Weight changes in celebrities can result from countless factors including diet, exercise, stress, illness, or other medications.
This type of armchair diagnosis does real harm by stigmatizing both the medications and people who need them for diabetes or obesity treatment.
What should you actually know about facial changes?
Facial volume loss is more likely with faster weight loss and in people over 40, when skin elasticity naturally decreases. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found 22.5% weight loss with 15mg tirzepatide, which could definitely cause noticeable facial changes in some patients.
If you're concerned about facial volume loss, discuss your weight loss goals and timeline with your healthcare provider. Slower, more gradual weight reduction may minimize facial changes.
Some patients work with dermatologists or plastic surgeons during significant weight loss to address skin and volume changes as they occur.